Biomerica, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
BMRA Nasdaq 3840 www.biomerica.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biomerica, Inc.

Biomerica’s tests for IBD conditions gain CE-marking under EU’s IVDR - Feb 27th, 2025 10:18 am
Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis - Feb 26th, 2025 1:19 pm
February 2025's Top US Penny Stocks To Consider - Feb 19th, 2025 8:11 pm
Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal - Feb 19th, 2025 1:19 pm
January 2025 US Penny Stocks With Promising Potential - Jan 17th, 2025 5:04 pm
Biomerica’s prostate cancer detection test gains approval from MOHAP - Jan 17th, 2025 3:48 pm
Top Midday Gainers - Jan 16th, 2025 6:01 pm
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer - Jan 16th, 2025 1:19 pm
Biomerica Second Quarter 2025 Earnings: US$0.055 loss per share (vs US$0.09 loss in 2Q 2024) - Jan 16th, 2025 11:07 am
Biomerica Reports Second Quarter Fiscal 2025 Financial Results - Jan 15th, 2025 1:19 pm
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis - Nov 21st, 2024 1:19 pm
Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements - Nov 7th, 2024 2:09 pm
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain - Oct 30th, 2024 12:19 pm
Biomerica Reports First Quarter Fiscal 2025 Financial Results - Oct 16th, 2024 1:00 pm
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer - Sep 4th, 2024 12:19 pm
Biomerica Full Year 2024 Earnings: US$0.35 loss per share (vs US$0.50 loss in FY 2023) - Aug 31st, 2024 1:55 pm
Biomerica Reports Fiscal 2024 Year End Results - Aug 29th, 2024 1:00 pm
Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers - Jul 1st, 2024 11:47 am
Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024 - May 13th, 2024 12:19 pm
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement - Apr 29th, 2024 12:19 pm